• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    STAAR Surgical (STAA) Stock Price Shrugs Off Profit Rebound As China Dominates

    Simply Wall St·08/13/2026 23:23:48
    Listen to the news

    STAAR Surgical stock barely flinched after earnings, slipping just 0.3% to about US$25 even though the quarter marked a clean break from last year’s bruising losses. The market came in wary after a rough 90 days for the stock and a history of red ink. The headline this time is simple. Q2 brought a clear return to profit with net income of US$8.1m and basic earnings per share of US$0.16, backed by US$93.5m of sales and a cash pile of US$181.5m with no debt.

    Is STAAR Surgical a genuine discount, with a DCF estimate above the current US$25 share price, or just expensive on rich P/S multiples? Compare the story for yourself on our valuation analysis for STAAR Surgical

    Q2 2026 Earnings Summary

    • Revenue, Q2 2026 vs. Q2 2025: US$93.5m vs. US$44.3m (increase of a little over 2x)
    • Net Income, Q2 2026 vs. Q2 2025: US$8.1m profit vs. US$16.8m loss (returned to profit)
    • Basic EPS, Q2 2026 vs. Q2 2025: US$0.16 vs. a loss of US$0.34 per share (returned to positive EPS)
    • Gross Margin, Q2 2026 vs. Q2 2025: 74.5% vs. 74.0% (slight margin improvement)

    Tired of scrolling through dense earnings reports and raw figures trying to piece together what really changed for STAAR Surgical this quarter? Get a clear, visual view of the latest profitability shift and the rest of the company’s financial picture in our company report for STAAR Surgical.

    NasdaqGM:STAA Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    NasdaqGM:STAA Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Evaluating STAAR Surgical’s China and Margin Bull Case

    The bullish story on STAAR Surgical is that a China inflection plus manufacturing and product execution can reset both growth and profitability. Q2 goes a fair way toward proving that out. China delivered US$52.3m of net sales and more than doubled year on year, while EVO Plus already represents about one third of China units and is supporting higher average selling prices. Management is clear that this is end demand, not inventory build, which is a key milestone for anyone banking on a durable China recovery rather than a one off restocking spike.

    On the margin and scale side, gross margin nudged up to 74.5% even though tariffs on US made product into China are still a drag until Swiss production fully supplies that market. Combined with positive net income and adjusted EBITDA of US$20m, Q2 provides concrete evidence that the higher volume thesis can translate into real profit, not just headline revenue growth.

    Compare this renewed profitability story for STAAR Surgical with how institutional forecasts are shifting. See the consensus price target analysis for STAAR Surgical to check whether Wall Street targets are moving in the same direction as the operations.

    STAAR Surgical Bear Case: Dependence, Durability, And Visibility

    The core bearish worry on STAAR Surgical is that heavy reliance on the ICL franchise, China driven volume and limited visibility on future demand makes current profitability fragile rather than durable. Q2 does not fully clear that hurdle. More than half of revenue still comes from China and growth outside China was modest, which means the business is still leaning heavily on a single product category and one key market. Tariffs continue to weigh on gross margin until Swiss manufacturing fully supports China, so the geopolitical and supply chain risk remains unresolved. Management again avoided formal revenue guidance and is asking investors to adjust for prior one time orders when thinking about the back half of 2026. That helps explain why the stock is roughly flat after such strong headline growth. The print answers some questions on execution but leaves durability and diversification concerns intact.

    With STAAR Surgical still carrying a history of rising losses and trading on a premium P/S multiple, many investors quietly worry about cash strength and funding risk. Check the hard liquidity, solvency and runway data in our financial health analysis of STAAR Surgical stock.

    Stay Ahead With Simply Wall St

    If the sharp swing back to profit at STAAR Surgical has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and spot an entry point that fits your plan. After you take a position, keep your focus on the essentials by using the Portfolio Command Center which surfaces key developments without drowning you in noise. For a longer term view, compare your thinking with thousands of other investors through the Community and see what angles you might have missed. By surfacing potential catalysts and risks early, Simply Wall St helps you act with confidence and stay a step ahead of the market.

    Seeking Fresh Alternatives Beyond STAAR Surgical

    Fresh ideas tend to move first when momentum picks up, and early breakouts often get identified quickly. Scan under the radar for now, before the crowd closes the gap, and consider acting while opportunities may still be developing.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.